Immune Support Protocol — Thymosin Alpha-1 + LL-37

VialKing

ADVANCED · P2

Thymosin Alpha-1 is FDA-orphan-designated and extensively studied for immune modulation. LL-37 is a cathelicidin antimicrobial peptide with broad-spectrum activity. The combination targets adaptive and innate immunity respectively.

TA1 enhances T-cell and dendritic cell function while LL-37 directly disrupts microbial membranes and modulates inflammatory signaling.

PROTOCOL PARAMETERS

Compound	Dose	Frequency	Route
Thymosin Alpha-1	1.6mg	2x weekly	SubQ
LL-37	100mcg	Daily	SubQ

Duration:8 weeks

Goals:Immune system research — adaptive + innate immunity dual modulation

Comments (0)

No comments yet. Start the thread.

Keep Researching

Compare Prices

Vendor pricing across the network

Explore Compounds

The full research database

Run the Math

Reconstitution and dosing calculators

← Back to the Asylum feed